Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).
We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.
Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.
Latest Media Releases
Latest News
Market Reports /
by Lauren Hayes -
A year ago
14 Nov 2022 - Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise in commodity pri…
Market Reports /
by Peter Milios -
A year ago
03 Nov 2022 - All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points.
Market Reports /
by Lauren Hayes -
A year ago
03 Nov 2022 - US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent inflation. Markets had initially so…
Market Reports /
by Peter Milios -
A year ago
01 Nov 2022 - Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as tech stocks weighed on the major inde…
Market Reports /
by Peter Milios -
A year ago
26 Oct 2022 - CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise.
Market Reports /
by Lauren Hayes -
A year ago
26 Oct 2022 - The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less aggressive, combined with a decline i…
Market Reports /
by Peter Milios -
A year ago
25 Oct 2022 - In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based digital currency Qoin, clai…
Market Reports /
by Lauren Hayes -
A year ago
25 Oct 2022 - Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports boosted sentim…
Interviews /
by Tim McGowen -
A year ago
12 Oct 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the compan…
Market Reports /
by Peter Milios -
A year ago
06 Oct 2022 - The ASX’s two-day positive run has turned to three days. It finished the day having increased slightly by 0.03 per cent or 1.80 points higher to 6817.50.
Market Reports /
by Lauren Hayes -
A year ago
04 Oct 2022 - It was a stellar performance for the S&P/ASX 200 today, which soared 3.75 per cent or 242.40 points to 6699.30, with all 11 sectors performing well at the closing bel…
Market Reports /
by Lauren Hayes -
A year ago
04 Oct 2022 - The ASX is enjoying a solid rally in Tuesday's morning session with all 11 sectors in the green following Wall Street's run overnight. It was the best day since June …
Market Reports /
by Paul Sanger -
A year ago
30 Aug 2022 - The ASX had a solid start to the trading session Tuesday, recovering some of yesterday's material fall. Japan jobless rate remains steady. US businesses more worried …
Market Reports /
by Melissa Darmawan -
A year ago
06 Jul 2022 - The Australian sharemarket has been choppy this morning in a zig-zag fashion. Information technology shares are leading the gains while resources stocks are lagging, …
Company News /
by Lauren Evans -
A year ago
06 Jul 2022 - Immutep (ASX:IMM) has been granted a Japanese patent for its IMP761, an immunosuppressive agonist antibody targeting LAG-3 for autoimmune diseases.
Market Reports /
by Melissa Darmawan -
A year ago
06 Jun 2022 - The Australian sharemarket has retreated this morning after three weeks of gains ahead of the Reserve Bank of Australia policy meeting tomorrow.
Company Presentations /
by -
A year ago
25 May 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint, Immutep's LAG-3 pipeline,…
Market Reports /
by Melissa Darmawan -
A year ago
11 May 2022 - Wall St closed mixed lifted by information tech and M&A news in the biotech sector as dip buyers emerge ahead of the next CPI print. Shanghai stocks bucked the trend …
Market Reports /
by Melissa Darmawan -
A year ago
04 May 2022 - Australian stocks are choppy today, at one point rebounding after two days of losses as energy and banks rally, offsetting losses by flight and travel stocks. The mar…
Interviews /
by Melissa Darmawan -
2 years ago
30 Mar 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for…
Interviews /
by Melissa Darmawan -
2 years ago
30 Mar 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses encouraging results in second-line non-small cell lung cancer.